| Objective:(1) To measure the plasma Epoxyeicosatrienoic acids(EETs) levels in patients with coronary heart disease and age-,sex-matched controls,in order to investigate the relationship between EETs and coronary heart disease.(2) Measure the effects of soluble epoxide hydrolase inhibitor-AEPU on the expression of VEGF in endothelial progenitor cells(EPCs) from patients with coronary heart disease by using western blot.Methods:(1) Sixty samples of peripheral venous blood were drawn into blood collecting tubes containing EDTA anticoagulant,centrifuged at 1500r/min for 10 minutes at room temperature,and stored at -80℃until analysis. Serum high sensitivity C-reactive protein(hs-CRP),total cholesterol(TC), triglyceride(TG),high density lipoprotein-cholesterol(HDL-C),and low density lipoprotein-cholesterol(LDL-C) concentrations were measured with a Hirachi 7170A analyzer by a specialist who was unaware of the study assignment.(2) Enzyme-linked immunosorbent assay was used to measure the plasma EETs levels.(3) Segregate,culture and identify EPCs,the expression of VEGF in EPCs from patients with coronary heart disease were measured by western blot after stimulated by AEPU.Results:(1) The levels of EETs(60.01±35.06ng/ml) were significantly lower in patients with coronary heart disease compared to those in control group (88.07±33.60ng/ml,p＜0.05),and the levels of EETs were inversely correlated with hs-CRP(R=-0.286,p=0.027).(2) AEPU can increase the the expression of VEGF in EPCs from patients with coronary heart disease.Conclusion:The levels of EETs were significantly lower in patients with coronary heart disease,and AEPU can increase the expression of VEGF in EPCs from patients with coronary heart disease,suggesting the potential predictive significance of sEHI in the therapy of coronary heart disease.
|
PDF Full Text Request